UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 139

Sortiert nach

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice

Breast cancer research : BCR, 2021-03, Vol.23 (1), p.37-37, Article 37

2021

Volltextzugriff (PDF)

Invasive lobular carcinoma: an understudied emergent subtype of breast cancer

Breast cancer research and treatment, 2022-06, Vol.193 (2), p.253-264

2022

Volltextzugriff (PDF)

Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis

Clinical breast cancer, 2022-08, Vol.22 (6), p.601-610

2022

Volltextzugriff (PDF)

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions

Targeted oncology, 2018-02, Vol.13 (1), p.21-38

2018

Volltextzugriff (PDF)

Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients

Breast cancer research : BCR, 2014-03, Vol.16 (2), p.R23-R23, Article R23

2014

Volltextzugriff (PDF)

Real‐world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database

International journal of cancer, 2024-02, Vol.154 (4), p.701-711

2024

Volltextzugriff (PDF)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer

Breast (Edinburgh), 2023-06, Vol.69, p.375-381

2023

Volltextzugriff (PDF)

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice

Targeted oncology, 2021-09, Vol.16 (5), p.601-611

2021

Volltextzugriff (PDF)

Yoga's Impact on Inflammation, Mood, and Fatigue in Breast Cancer Survivors: A Randomized Controlled Trial

Journal of clinical oncology, 2014-04, Vol.32 (10), p.1040-1049

2014

Volltextzugriff (PDF)

Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma

The oncologist (Dayton, Ohio), 2024-03, Vol.29 (3), p.213-218

2024

Volltextzugriff (PDF)

Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study

International journal of cancer, 2022-06, Vol.150 (12), p.2025-2037

2022

Volltextzugriff (PDF)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer

The oncologist (Dayton, Ohio), 2023-10, Vol.28 (10), p.866-874

2023

Volltextzugriff (PDF)

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis

Frontiers in oncology, 2022-07, Vol.12, p.865292-865292

2022

Volltextzugriff (PDF)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

NPJ breast cancer, 2022-10, Vol.8 (1), p.114-114, Article 114

2022

Volltextzugriff (PDF)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older

Frontiers in oncology, 2023-09, Vol.13, p.1237751-1237751

2023

Volltextzugriff (PDF)

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer

Clinical cancer research, 2021-11, Vol.27 (21), p.5760-5770

2021

Volltextzugriff (PDF)

Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors

Clinical cancer research, 2013-03, Vol.19 (6), p.1512-1524

2013

Volltextzugriff (PDF)

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

The lancet oncology, 2024-04, Vol.25 (4), p.474-487

2024

Volltextzugriff (PDF)

Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary

Future oncology (London, England), 2024-06, Vol.20 (19), p.1309-1317

2024

Volltextzugriff (PDF)

Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study

Future oncology (London, England), 2024-06, Vol.20 (19), p.1299-1307

2024

Volltextzugriff (PDF)

Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice

Cancers, 2023-11, Vol.15 (21), p.5268

2023

Volltextzugriff (PDF)

Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis

Oncoimmunology, 2021-01, Vol.10 (1), p.1877415-1877415

2021

Volltextzugriff (PDF)

Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Clinical cancer research, 2024-06, Vol.30 (11), p.2424

2024

Volltextzugriff (PDF)

A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer

Clinical cancer research, 2024-01, Vol.30 (2), p.334

2024

Volltextzugriff (PDF)

Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial

Nature medicine, 2024-06, Vol.30 (8), p.2242-2250

2024

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(127)

Publikationsform

Artikel
(137)
Berichte
(2)

Sprache

Englisch
(139)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(77)
Life Sciences & Biomedicine
(74)
Oncology
(63)
Humans
(54)
Female
(49)
Breast Cancer
(43)
Breast Neoplasms - Drug Therapy
(35)
Middle Aged
(26)
Adult
(22)
Breast Neoplasms - Pathology
(22)
Aged
(21)
Metastasis
(19)
Patients
(19)
Medicine
(17)
Medicine & Public Health
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Metastatic Breast Cancer
(15)
Chemotherapy
(14)
Endocrine Therapy
(12)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice

Invasive lobular carcinoma: an understudied emergent subtype of breast cancer

Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions

Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients

Real‐world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice

Yoga's Impact on Inflammation, Mood, and Fatigue in Breast Cancer Survivors: A Randomized Controlled Trial

Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma

Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer

Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary

Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study

Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice

Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis

Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer

Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial

Suchergebnisse filtern